Form 4: Recursion Pharmaceuticals CEO Christopher Gibson Reports Tax Withholding Share Transaction
SEC Form 4 Filing
CEO Christopher Gibson reports the withholding of 36,197 Class A Common Stock shares by Recursion Pharmaceuticals to cover tax obligations related to restricted stock units.
Summary
- On May 15, 2025, Christopher Gibson, CEO of Recursion Pharmaceuticals, reported a transaction involving Class A Common Stock.
- The transaction involved the withholding of 36,197 shares by the issuer to satisfy tax withholding obligations related to the net settlement of restricted stock units at a price of $4.25.
- Following the transaction, Gibson directly owns 1,081,253 shares of Class A Common Stock.
- Gibson also indirectly owns shares through LAHWRAN-3 LLC (486,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (67,875 shares).
- Gibson holds options to purchase a total of 2,937,403 shares of Class A Common Stock at various exercise prices and expiration dates.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a routine transaction (tax withholding). It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions and is a standard practice for publicly traded companies. It provides transparency into the holdings and transactions of company executives.
Comparison to Industry Standards
- Form 4 filings are a standard requirement for corporate insiders in publicly traded companies, ensuring transparency and compliance with SEC regulations.
- Similar filings are made by executives at comparable companies like Exscientia, Schrödinger, and Relay Therapeutics, reflecting their stock ownership and transactions.
Stakeholder Impact
- The transaction has a minimal direct impact on shareholders, as it relates to tax obligations of the CEO.
- The withholding of shares could slightly reduce the number of outstanding shares, but the effect is likely negligible.
Key Dates
| Date | Description |
|---|---|
| 02/04/2022 | Initial vesting date for stock option with exercise price of $11.4 |
| 02/01/2023 | Initial vesting date for stock option with exercise price of $8.55 |
| 02/09/2024 | Initial vesting date for stock option with exercise price of $10.09 |
| 03/01/2024 | First vesting date for options exercisable at $10.09. |
| 03/01/2025 | First vesting date for options exercisable at $7.25. |
| 05/15/2025 | Date of the reported transaction (tax withholding of shares). |
| 05/19/2025 | Date of signature for the Form 4 filing. |
| 02/01/2033 | Expiration date for stock option with exercise price of $8.55 |
| 02/09/2034 | Expiration date for stock option with exercise price of $10.09 |
| 02/03/2035 | Expiration date for stock option with exercise price of $7.25 |
Keywords
Form 4, Christopher Gibson, Recursion Pharmaceuticals, RXRX, insider trading, Class A Common Stock, tax withholding, restricted stock units, CEO, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.